116 related articles for article (PubMed ID: 27959446)
1. The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance (Review).
Miekus K
Oncol Rep; 2017 Feb; 37(2):647-656. PubMed ID: 27959446
[TBL] [Abstract][Full Text] [Related]
2. C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.
Marona P; Górka J; Kotlinowski J; Majka M; Jura J; Miekus K
Cells; 2019 Mar; 8(3):. PubMed ID: 30909397
[TBL] [Abstract][Full Text] [Related]
3. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
4. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Luraghi P; Reato G; Cipriano E; Sassi F; Orzan F; Bigatto V; De Bacco F; Menietti E; Han M; Rideout WM; Perera T; Bertotti A; Trusolino L; Comoglio PM; Boccaccio C
Cancer Res; 2014 Mar; 74(6):1857-69. PubMed ID: 24448239
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
[TBL] [Abstract][Full Text] [Related]
6. Head neck squamous cell carcinoma c-Met⁺ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis.
Sun S; Wang Z
Int J Cancer; 2011 Nov; 129(10):2337-48. PubMed ID: 21225626
[TBL] [Abstract][Full Text] [Related]
7. [Cancer Stem Cells (CSCs) as a Rational Therapeutic Cancer Target, and Screening for CSC-targeting Drugs].
Mashima T
Yakugaku Zasshi; 2017; 137(2):129-132. PubMed ID: 28154319
[TBL] [Abstract][Full Text] [Related]
8. C-MET as a potential target therapy toward personalized therapy in some pediatric tumors: An overview.
Rashed WM
Crit Rev Oncol Hematol; 2018 Nov; 131():7-15. PubMed ID: 30293708
[TBL] [Abstract][Full Text] [Related]
9. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
10. MET receptor tyrosine kinase as a therapeutic anticancer target.
Stellrecht CM; Gandhi V
Cancer Lett; 2009 Jul; 280(1):1-14. PubMed ID: 19100682
[TBL] [Abstract][Full Text] [Related]
11. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell.
Lim YC; Kang HJ; Moon JH
Oral Oncol; 2014 Jul; 50(7):633-9. PubMed ID: 24835851
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem cells and their potential implications for the treatment of solid tumors.
Grotenhuis BA; Wijnhoven BP; van Lanschot JJ
J Surg Oncol; 2012 Aug; 106(2):209-15. PubMed ID: 22371125
[TBL] [Abstract][Full Text] [Related]
13. The bad seed gardener: Deubiquitinases in the cancer stem-cell signaling network and therapeutic resistance.
Qiu GZ; Sun W; Jin MZ; Lin J; Lu PG; Jin WL
Pharmacol Ther; 2017 Apr; 172():127-138. PubMed ID: 27919796
[TBL] [Abstract][Full Text] [Related]
14. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Comoglio PM; Giordano S; Trusolino L
Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
[TBL] [Abstract][Full Text] [Related]
15. Progress in cancer therapy targeting c-Met signaling pathway.
Jung KH; Park BH; Hong SS
Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
[TBL] [Abstract][Full Text] [Related]
16. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
17. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
18. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
Sadiq AA; Salgia R
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S372-4. PubMed ID: 23160322
[No Abstract] [Full Text] [Related]
20. Liver cancer stem cell markers: Progression and therapeutic implications.
Sun JH; Luo Q; Liu LL; Song GB
World J Gastroenterol; 2016 Apr; 22(13):3547-57. PubMed ID: 27053846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
